Wednesday, November 19, 2025 Secondary analysis publication using data from IND223, IND232 and IND234. Somatic alterations to the androgen receptor (AR) gene are pivotal drivers of treatment resistance in metastatic castration-resistant prostate cancer (mCRPC), but their prevalence, clinical impact, and etiology remain incompletely understood. Virtanen T, Kwan EM, Parekh K, Bacon JVW, Huang CF, Yu IPL, Ryyppö L, Bernales C, Donnellan G, Tam C, Sipola J, Nikkola J, Vandekerkhove G, Tolmeijer SH, Kukkonen K, Adelia, Eigl BJ, Finch D, Gagnon R, Takieldeen Y, Hardy E, Khalaf D, Kollmannsberger C, Lavoie JM, Maurice-Dror C, Miller S, Nappi L, Noonan K, Parimi S, Riminchan A, Sartori-Mueller E, Soleimani M, Vergidis J, Zulfiqar M, Hansen A, Hotte S, Jafri M, Kolinsky M, Mukherjee SD, Ong M, Rose AAN, Tu W, Winquist E, Bergman AM, van der Zande K, Zwart W, Mehra N, van Erp NP, Zhao JL, Rathkopf D, Barbieri C, Quigley D, Nykter M, Lack NA, Chi KN, Annala M, Wyatt AW. Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer (ONLINE). Annals of Oncology 2025. https://doi.org/10.1016/j.annonc.2025.10.1236
